{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:52:06Z","timestamp":1793350326095,"version":"4.5.0"},"reference-count":29,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"UK Department for International Development","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2020,11,11]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>With political will, modest financial investment and effective technical assistance, public sector hepatitis C virus (HCV) programmes can be established in low- and middle-income countries as a first step towards elimination. Seven countries, with support from the Clinton Health Access Initiative (CHAI) and partners, have expanded access to HCV treatment by combining programme simplification with market shaping to reduce commodity prices. CHAI has supported a multipronged approach to HCV programme launch in Cambodia, India, Indonesia, Myanmar, Nigeria, Rwanda and Vietnam including pricing negotiations with suppliers, policy development, fast-track registrations of quality-assured generics, financing advocacy and strengthened service delivery. Governments are leading programme implementation, leveraging HIV programme infrastructure\/financing and focusing on higher-HCV prevalence populations like people living with HIV, people who inject drugs and prisoners. This manuscript aims to describe programme structure and strategies, highlight current commodity costs and outline testing and treatment volumes across these countries. Across countries, commodity costs have fallen from &gt;US$100 per diagnostic test and US$750\u2013US$900 per 12-week pan-genotypic direct-acting antiviral regimen to as low as US$80 per-cure commodity package, including WHO-prequalified generic drugs (sofosbuvir + daclatasvir). As of December 2019, 5900+ healthcare workers were trained, 2 209 209 patients were screened, and 120 522 patients initiated treatment. The cure (SVR12) rate was &gt;90%, including at lower-tier facilities. Programmes are successfully implementing simplified, decentralised public health approaches. Combined with political will and affordable pricing, these efforts can translate into commitments to achieve global targets. However, to achieve elimination, additional investment in scale-up is required.<\/jats:p>","DOI":"10.1136\/bmjgh-2020-003767","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T17:52:00Z","timestamp":1608141120000},"page":"e003767","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":49,"title":["Initial success from a public health approach to hepatitis C testing, treatment and cure in seven countries: the road to elimination"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-1307","authenticated-orcid":false,"given":"Caroline E","family":"Boeke","sequence":"first","affiliation":[{"name":"Clinton Health Access Initiative, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Adesigbin","sequence":"additional","affiliation":[{"name":"National AIDS\/STIs Control Programme, Federal Ministry of Health, Nigeria, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuemeka","family":"Agwuocha","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiek","family":"Anartati","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hlaing Thazin","family":"Aung","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Yangon, Myanmar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khin Sanda","family":"Aung","sequence":"additional","affiliation":[{"name":"National Hepatitis Control Program, Department of Public Health, Ministry of Health and Sports, Yangon, Myanmar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep Singh","family":"Grover","sequence":"additional","affiliation":[{"name":"Department of Health and Family Welfare, National Viral Hepatitis Control Program, Government of Punjab, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dang","family":"Ngo","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Hanoi, Viet Nam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida","family":"Ngwije","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin","family":"Nsanzimana","sequence":"additional","affiliation":[{"name":"Rwanda Biomedical Center, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Sindhwani","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Singh","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ly Penh","family":"Sun","sequence":"additional","affiliation":[{"name":"National Center for HIV\/AIDS, Dermatology, and Infectious Disease, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Van","family":"Kinh","sequence":"additional","affiliation":[{"name":"National Hospital of Tropical Diseases, Hanoi, Viet Nam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiendra","family":"Waworuntu","sequence":"additional","affiliation":[{"name":"Directorate of Communicable Disease Prevention and Control, Ministry of Health of the Republic of Indonesia, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"McClure","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"2025073014512706000_5.12.e003767.1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"2025073014512706000_5.12.e003767.2","unstructured":"World Health Organization . Guidelines for the care and treatment of persons diagnosed with chronic HCV infection. Geneva, Switzerland, 2018."},{"key":"2025073014512706000_5.12.e003767.3","unstructured":"World Health Organization . Combating hepatitis B and C to reach elimination by 2030, 2016."},{"key":"2025073014512706000_5.12.e003767.4","unstructured":"AASLD, EASL, APASL, ALEH . Call to action for liver associations to advance progress towards viral hepatitis elimination: a focus on simplified approaches to HCV testing and cure, 2019."},{"key":"2025073014512706000_5.12.e003767.5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.15.1632"},{"key":"2025073014512706000_5.12.e003767.6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.996"},{"key":"2025073014512706000_5.12.e003767.7","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16132345"},{"key":"2025073014512706000_5.12.e003767.8","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13311"},{"key":"2025073014512706000_5.12.e003767.9","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14466"},{"key":"2025073014512706000_5.12.e003767.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200461"},{"key":"2025073014512706000_5.12.e003767.11","unstructured":"Ministry of Health, Republic of Indonesia . National health survey, 2013."},{"key":"2025073014512706000_5.12.e003767.12","unstructured":"Lwin AAA , Htun K.S.; , Kyaw M.M.; , et al . Sero-Prevalence of hepatitis B and C viral infections in Myanmar: national and regional survey in 2015. Myanmar Helath Science Research Journal 2017;29."},{"key":"2025073014512706000_5.12.e003767.13","unstructured":"Nigeria National HIV\/AIDS . Impact and indicator survey, 2018."},{"key":"2025073014512706000_5.12.e003767.14","first-page":"274","article-title":"Prevalence of hepatitis B and C virus infection among people of a local community in Keffi, Nigeria","volume":"4","author":"Pennap","year":"2010","journal-title":"African Journal of Microbiology Research"},{"key":"2025073014512706000_5.12.e003767.15","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2013.14.44.2199"},{"key":"2025073014512706000_5.12.e003767.16","unstructured":"World Health Organization, Western Pacific Region . Viral hepatitis situation and response in Viet Nam. Manila, Philippines, 2018."},{"key":"2025073014512706000_5.12.e003767.17","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30272-4"},{"key":"2025073014512706000_5.12.e003767.18","unstructured":"Clinton Health Access Initiative (CHAI) . Hepatitis C market report, 2020."},{"key":"2025073014512706000_5.12.e003767.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.012"},{"key":"2025073014512706000_5.12.e003767.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00485-5"},{"key":"2025073014512706000_5.12.e003767.21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26387"},{"key":"2025073014512706000_5.12.e003767.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2016.06.012"},{"key":"2025073014512706000_5.12.e003767.23","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14328"},{"key":"2025073014512706000_5.12.e003767.24","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16020231"},{"key":"2025073014512706000_5.12.e003767.25","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-016-3671-z"},{"key":"2025073014512706000_5.12.e003767.26","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/cid\/cit263","article-title":"Understanding barriers to hepatitis C virus care and stigmatization from a social perspective","volume":"57 Suppl 2","author":"Treloar","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025073014512706000_5.12.e003767.27","unstructured":"World Hepatitis Alliance and Clinton Health Access Initiative (CHAI) . Developing an HCV investment case for Punjab (India), 2020."},{"key":"2025073014512706000_5.12.e003767.28","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14232"},{"key":"2025073014512706000_5.12.e003767.29","unstructured":"World Bank Group . Population estimates and projections, 2019."}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2020-003767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T21:51:35Z","timestamp":1753912295000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2020-003767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,15]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bmjgh-2020-003767"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2020-003767","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}